StreetInsider.com News Articles

Xenetic Biosciences doses first patient in DNase and CAR T-cell study

Thu, 15 Oct 2026 08:46:53 -0400

Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced that its collaboration partner, PeriNess Ltd., has dosed the first patient in an investigator-initiated clinical study evaluating systemic recombinant human DNase in combination with anti-CD19 CAR T-cell therapy for large B-cell lymphoma (LBCL) at the Tel Aviv Sourasky University Medical Center in Israel.

The study was approved by the Israeli Ministry of Health and the applicable Institutional Review Board in June 2026. It is enrolling 12 patients with LBCL who have stable or progressive disease prior to lymphodepletion therapy, a population with a one-year progression-free survival of approximately 20% to 30%.

Patients will receive a commercial

Xenetic Biosciences doses first patient in DNase and CAR T-cell study

Thu, 15 Oct 2026 08:46:53 -0400

Patients will receive a commercial

Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells f

Thu, 15 Oct 2026 08:46:00 -0400

FRAMINGHAM, MA / ACCESS Newswire / October 15, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. ("PeriNess"), has informed the Company that the first patient has been dosed in an investigator-initiated clinical study evaluating systemic recombinant human DNase in combination with anti-CD19 CAR T-cell therapy in patients with large B-cell lymphoma ("LBCL") at the Tel Aviv Sourasky University Medical Center ("Ichilov Center") in Israel.

The milestone marks

Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells f

Thu, 15 Oct 2026 08:46:00 -0400

The milestone marks

Form 8-K Xenetic Biosciences, For: Sep 23

Wed, 23 Sep 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260923/27097450.html

Form SCHEDULE 13G Xenetic Biosciences, Filed by: MJL Manager LLC

Fri, 18 Sep 2026 14:36:00 -0400

si-local-file:///var/storage/secattach/20260918/27080172.html

Xenetic Biosciences to acquire Santersus AG in all-stock deal

Wed, 16 Sep 2026 07:01:38 -0400

Xenetic Biosciences, Inc. (NASDAQ: XBIO) and privately held Santersus AG have entered into a definitive share exchange agreement under which Xenetic will acquire all outstanding share capital of Santersus in an all-stock transaction, the companies announced on September 16, 2026.

Under the terms of the agreement, current Xenetic stockholders and Santersus equity holders would own approximately 15% and 85%, respectively, of the combined company on a fully diluted basis, subject to adjustment. The combined company is expected to trade on the Nasdaq Capital Market under the name Santersus Bio, Inc. with the ticker symbol "SNTS."

The transaction would combine Santersus' NucleoCapture® selective

Xenetic Biosciences to acquire Santersus AG in all-stock deal

Wed, 16 Sep 2026 07:01:38 -0400

The transaction would combine Santersus' NucleoCapture® selective

Form 8-K Xenetic Biosciences, For: Sep 14

Wed, 16 Sep 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260916/27067290.html

Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

Wed, 16 Sep 2026 07:00:00 -0400

Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps (NETs), a driver of disease across critical care, autoimmune disease, transplantation and oncology

Union of two companies brings together Santersus' NucleoCapture® technology, designed to physically remove NETs from circulation, with Xenetic's DNase technology, designed to enzymatically degrade NETs in tissue

Joint pipeline includes four first-in-class programs, including pivotal-stage programs in sepsis and systemic lupus erythematosus (SLE), both of which have received FDA Breakthrough Device Designation

Companies to host Business Update Conference Call and Webcast Today, Wednesday, September 16^th at 8:30 AM ET

Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

Wed, 16 Sep 2026 07:00:00 -0400

Companies to host Business Update Conference Call and Webcast Today, Wednesday, September 16^th at 8:30 AM ET

Form 8-K Xenetic Biosciences, For: Aug 07